Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528781 | 0.94 | KMT2A (0.60) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL178805 | 0.94 | KMT2A (0.60) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL29401303 | 0.94 | KMT2A (0.60) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL178804 | 0.94 | KMT2A (0.60) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL3487948 | 0.94 | KMT2A (0.60) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL26310750 | 0.92 | KMT2A (0.59) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL25357184 | 0.91 | MDM4 (0.54) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL31210302 | 0.91 | MDM4 (0.54) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL25357189 | 0.91 | MDM4 (0.54) | MDM2MDM4TP53KMT2ATLR2 | |
| SCHEMBL30385460 | 0.89 | MDM2 (0.57) | MDM2MDM4TP53KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662960-B2 | Beta-strand mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-02-16 | — | — | US | disclosed |
| EP-1646633-B1 | BETA-STRAND MIMETICS | CHOONGWAE PHARMA CORP (KR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1646633-A1 | BETA-STRAND MIMETICS AND METHOD RELATING THERETO | Choongwae Pharma Corporation (KR) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004108731-A1 | BETA-STRAND MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2004-12-16 | — | — | WO | disclosed |
| US-20040053331-A1 | Beta-strand mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053331-A1 | Beta-strand mimetics and method relating thereto | BIRC5, BIRC7, XIAP | MDM2 247/4885MDM4 643/4885TP53 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.